D. Western Therapeutics Institute, Inc. Reports Consolidated Earnings Results for the Nine Months Ended September 30, 2020
November 13, 2020 at 01:30 am EST
Share
D. Western Therapeutics Institute, Inc. reported consolidated earnings results for the nine months ended September 30, 2020. For the period, the company reported net sales of JPY 240,547,000 compared to JPY 451,815,000 a year ago. Operating loss was JPY 147,696,000 compared to profit of JPY 107,333,000 a year ago. Loss was JPY 165,960,000 or JPY 5.70 per share compared to profit of JPY 98,426,000 or JPY 4.57 per share a year ago.
D.Western Therapeutics Institute, Inc. is a Japan-based company engaged in the research and development of new pharmaceuticals. The Company generates revenue from licensing of its developed drugs to other companies. As of December 31, 2012, the Companyâs drug pipeline included anti-thrombotic medicine K-134, therapeutic agent K-115 for glaucoma, and anticancer drug HMN-214. Its newly-developed products include new anti-thrombotic medicine and signal-transduction inhibitors, including therapeutic agent for high-blood pressure, protective agent for nerves, therapeutic agent for atherosclerosis, ophthalmologic drug and anticancer drug, among others. The Company is also developing new drug candidate compounds focusing on protein kinase inhibitors and involving in ophthalmic surgical adjuvant business, which includes ingredient of Brilliant Blue G-250.
D. WESTERN THERAPEUTICS INSTITUTE, INC. 
